Eli Lilly’s retatrutide beats Ozempic in Phase 3 head‑to‑head diabetes trial

Eli Lilly reported that its investigational triple‑hormone drug retatrutide produced a larger drop in A1C and more than double the weight loss of Novo Nordisk’s Ozempic in the 80‑week TRANSCEND‑T2D‑2 Phase 3 trial. The study enrolled about 1,300 adults with type 2 diabetes and compared retatrutide 9 mg and 12 mg doses against Ozempic 2 mg. Lilly’s executive said the data could shift the treatment paradigm if the drug receives approval.

Lilly says the results could shift the treatment paradigm for type 2 diabetes and obesity, opening a new premium product line. Analysts note the drug could generate up to $15 billion in sales by 2032, pressuring competitors.

  • 1Retatrutide lowered A1C by an average of 2.2% versus 1.8% for Ozempic 2 mg at 80 weeks.
  • 2Participants on retatrutide lost 44.3 lb (19.5%) at the 9 mg dose and 47.4 lb (20.9%) at the 12 mg dose, compared with 20.9 lb (9.4%) on Ozempic.
  • 3The trial enrolled 1,298 adults with type 2 diabetes.
  • 4Retatrutide was given at 9 mg and 12 mg once weekly.
  • 5Treatment discontinuation due to adverse events was 4.8% (9 mg) and 7.9% (12 mg) versus 2.7% for Ozempic.
  • 6The primary and all key secondary endpoints were met at 80 weeks.

Sources